• Mon. Jun 17th, 2024

Revolutionizing Gene Therapy Manufacturing with Viralgen’s Proprietary Pro10™ Cell Line

BySamantha Johnson

Mar 27, 2024
A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

In this paper, we explore the Pro10™ cell line, a new technology that enhances the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. The Pro10™ cell line is a proprietary mammalian suspension technology that enables the scalable and robust production of rAAVs, addressing the challenges associated with large-scale manufacturing in AAV gene therapies.

Viralgen leverages the Pro10™ cells as the core of its reliable and scalable rAAV vector manufacturing process. These cells have been optimized specifically for rAAV production and have successfully been scaled up to 2000L, demonstrating consistent and reproducible cell growth rates. They have shown similar productivity levels in both small and large-scale bioreactors and are capable of producing various AAV serotypes.

The Pro10™ cells play a critical role in Viralgen’s platform process for manufacturing AAV vectors and have significantly contributed to the production of innovative gene therapies. For more information about the HEK293 derived animal component-free suspension Pro10™ cell line, access our full PDF detailing its properties and potential benefits for reducing process development time and costs.

By Samantha Johnson

As a dedicated content writer at newsanguinely.com, I weave words into compelling stories that captivate and inform our readers. With a passion for storytelling and a keen eye for detail, I craft engaging articles that shed light on the latest news and trends. When I'm not typing away at my keyboard, you can find me exploring new ideas, researching diverse topics, and striving to deliver content that resonates with our audience. Join me on this journey as we uncover the stories that matter most.

Leave a Reply